Latest news with #Scorpion
Hypebeast
01-07-2025
- Entertainment
- Hypebeast
Westside Gunn Teases His Saucony Grid Jazz 9 'Scorpion'
Summary Last October,Westside Gunntook to Instagram toannouncehis first sneaker project, partnering withSaucony. We then saw him reveal a colorful, glow-in-the-dark take on theProGrid Triumph 4at the end of 2024. While the two have been quiet since, we now have another design to anticipate. Gunn and Saucony made their presence at Paris Fashion Week known by revealing another collaborative sneaker, theGrid Jazz 9'Scorpion.' Our limited first look at the pair sees the shoe dressed in an attention-commanding red. The monochromatic pair features a wide range of materials, including faux pony hair, textured leather, and suede at the upper. It also sports a large scorpion at the medial midfoot, a motif often used by Gunn's Griselda Records collective. At the time of writing, neither Westside Gunn nor Saucony have indicated when this red 'Scorpion' take on the Grid Jazz 9 will be dropping. Stay tuned for updates, including an official look at the pair, as we expect it to drop alongside additional designs from the new duo in the months to come.
Motor Trend
24-06-2025
- Automotive
- Motor Trend
Pirelli Scorpion XTM Tire Review: Passing the Desert Torture Test?
The Pirelli Scorpion XTM AT is the most rugged offering from the Italian tire maker, and we put it to work in the unforgiving terrain of the Mojave Desert. The Pirelli Scorpion XTM AT tire excels in rugged conditions, proving durable and effective on off-road SUVs like the Jeep Wrangler and Ford Bronco in the Mojave Desert. It offers strong grip and minimal wear, and is available in multiple sizes, including options for electric vehicles. This summary was generated by AI using content from this MotorTrend article Read Next Pirelli positions the Scorpion XTM as the next step in its Scorpion lineup, just ahead of the Scorpion All-Terrain Plus tire. Where the previous Scorpion might have looked tame, the Scorpion XTM AT glares at you with a chunky sidewall design that hints at the tire's rugged construction. Looking closer at the sidewall reveals another key feature of the Pirelli Scorpion XTM AT—the Three-Peak Mountain Snowflake (3PMSF) symbol. This means the tire is certified for severe snow service and should perform better than an average tire (accelerating in a straight line) on a packed-snow surface. Tread blocks are spaced to create larger voids than the average all-terrain tire, reinforcing the Scorpion XTM AT's ability to clear itself of mud when it spins. When driving on gravel, a common failure point for tires is when small stones become lodged in the tread and drill into the carcass, a process known as stone drilling. The Scorpion XTM AT has elements built between the treads to eject those stones before they can damage the tire. We put the Scorpion XTM AT to work beneath two popular off-road SUVs: the Jeep Wrangler Unlimited and the Ford Bronco Badlands. Owners of these vehicles often choose tires based on their off-road capability, reliability, and appearance; we sought to evaluate the tire in each of those aspects. When fit inside the wheelwells of the Wrangler and Bronco, the Scorpion XTM AT looked right at home. Where some tires just appear round and black, the Scorpion XTM AT asserts itself as aggressive the moment you lock eyes with its sidewall. We hit the desert—hard. Fifty miles of high-speed dirt track lay ahead of us, and the trail was littered with fist-sized rocks ready to tear into any unlucky sidewalls or tread patches. We dipped into the throttle and sent the SUVs ripping across the desert, free to steer with the rear end on the loose turns. When the rpms settled, we inspected the tires for any signs of chunking, dangling tread elements, or slashes to the sidewalls. This type of terrain has spelled disaster for many tires before, but we were impressed by how the Scorpion XTM AT fared. The tires barely looked used. Pointing the SUVs at a series of rocky hill climbs demonstrated more of the tire's off-road grip. Where some all-terrain tires spin and slip climbing up rocks, the Scorpion XTM AT used its large tread blocks and voids and clawed up every incline. Although it is in no way a sand paddle, we slashed across the dunes with ease. After the tires had seen a full day of relentless off-road punishment, we lapped the Broncos around a cone course in the dirt. No driver was shy about throttle application through the series of tight turns, and every part of the tire took a severe beating. Even after hours of lapping the brutal course, our only quasi-complaint was a few pebbles sneaking between the wheel and the bead—driver error, no fault of the Scorpion XTM AT. Damage report from the treadwear department: The entire fleet of tires looked next to brand-new. No flats, punctures, or sidewall traumas. Even tires on dedicated off-road rigs must behave on pavement, so we listened closely as we stepped up the speeds on the highway for signs of droning or the telltale 'whum, whum, whum' of a mudder passing by. You will hear more noise than your stock equipment if the Scorpion XTM AT replaces a garden-variety all-season tire. However, in the world of aggressive all-terrain tires, nothing is out of the ordinary. What Did We Learn? Our time with the Pirelli Scorpion XTM AT wasn't an instrumented test, we didn't compare the tire to any competing products, and our experience was on new tires for a few hundred miles. This was a chance to experience the tire's strengths and really find out if it would fail. We weren't gentle in any way, and since this gaggle of aggressive drivers didn't encounter so much as a sidewall blemish, it means we now vouch for the Scorpion XTM AT's durability. The Scorpion XTM AT is not just for Jeeps and Broncos. Pirelli offers select sizes of the tire with its Elect technology. This compound promotes low rolling resistance and targets electric vehicle (EV) drivers. We spent time with the Scorpion XTM AT under the Rivian R1S, an electric SUV with upwards of 600 horsepower that weighs more than three tons. Not only did the tire handle the electric SUV's incredible torque on the rocky trails, but it also looked stunning in the wheelwells. It's certainly more aesthetically pleasing than the All-Terrain Plus that was standard on some Rivian vehicles. We hope this new Pirelli will become standard on future Rivians. Pirelli Scorpion XTM AT Sizes The Pirelli Scorpion XTM AT is available now in select sizes and will ultimately be offered in 37 sizes for 17- to 24-inch wheels. Depending on size, you can have the Scorpion with a speed rating of R (106 mph), S (112 mph), or T (118 mph). Off-roaders will find common flotation sizes, as well.
Yahoo
11-06-2025
- General
- Yahoo
June full moon in Scorpio 2025: How often is there a strawberry moon? Watch tonight's sky
June's full moon, also known as the rare strawberry moon will appear tonight next to the bright red 'heart of the Scorpion' star, Antares in the constellation Scorpius during a Major Lunar Standstill. Here's what it all means. This month's special strawberry full moon will be the lowest full moon in decades because we are near what's called a Major Lunar Standstill — a phenomenon that occurs every 18.6 years when the moon's orbit is tilted at its maximum angle, reaching its highest and lowest points in the sky. Here's what to know about June's full strawberry moon, the moon phases and the summer solstice. The strawberry moon will reach peak illumination at 3:44 a.m. on June 11, 2025, according to the Almanac. To catch a glimpse, find a location with unobstructed views of the horizon. Click here to see moonrise and moonset times in your area. 🌓 First Quarter: June 2. 🌕 Full Moon: June 11. 🌗 Last Quarter: June 18. 🌑 New Moon: June 25. Similar to April's pink moon, June's strawberry moon gets its name from the seasonal berry harvest, according to the Old Farmer's Almanac. Ripening berries are traditionally ready to be harvested around this time in the northeastern United States. Albeit, while strawberries are in fact a reddish-pink color, the color of the moon is not reflective of the 'strawberry' name, but rather it gets its reddish glow when it is closer to the horizon and the light rays pass through the densest layers of the atmosphere. The June solstice will mark the longest day of the year in the Northern Hemisphere as it heralds the start of the new season of summer, which this year will begin at 10:42 p.m. ET on June 20, 2025. The July full moon, known as the buck moon, will be visible on July 10, 2025. This article originally appeared on Erie Times-News: June full moon 2025: What time will tonight's strawberry moon appear
Yahoo
11-06-2025
- Business
- Yahoo
Scorpion, fresh off Lilly deal, spins out startup Antares
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Fresh off a multibillion-dollar deal with Eli Lilly, cancer drug startup Scorpion Therapeutics is trying for an encore, debuting a successor company on Tuesday that's carrying forward much of its previous work. Called Antares Therapeutics, the startup is launching with $177 million in financing from nearly a dozen investors, among them previous backers Omega Funds and Atlas Venture. Antares will use that cash to advance a group of small molecule drugs Scorpion had been working on, as well as programs the company had been advancing through a 2022 partnership with AstraZeneca. Its work will specifically focus on cancer and other unspecified 'serious diseases,' according to a statement. The company didn't divulge more details about its pipeline, only noting on its website that its first program should begin human testing in 2026 and multiple others are in preclinical development. In a statement, CEO Adam Friedman, who previously ran Scorpion, said the company's research is "fueled by discoveries in drugging previously inaccessible targets.' Antares could also get future milestone payments and royalties from a pair of cancer drugs involved in a Scorpion alliance with Pierre Fabre Laboratories. Another startup, Moma Therapeutics, has rights to a PARP inhibitor Scorpion was advancing, too. Scorpion was co-founded in 2020 by Gary Glick, who helped the company raise nearly $300 million in venture funding before departing in 2021. Prior to Scorpion, Glick led Lycera, which formed a 2015 deal with Celgene, and IFM Therapeutics, which has spun off multiple companies that were acquired by larger drugmakers. Glick went on to lead inflammatory drug developer Odyssey Therapeutics, which has been trying to go public. In the meantime, Scorpion was helmed by Friedman, who helped the company raise additional funding, form multiple partnerships and generate six cancer drug candidates, three of which are in clinical testing, according to its statement. Scorpion sold one, dubbed STX-678, to Eli Lilly in January for as much as $2.5 billion. As part of that deal, it formed a new company holding its other assets and inheriting its employees. That company, now known as Antares, is supported by Scorpion's old shareholders and also led by Friedman. 'Antares will build on what Scorpion started: combining cutting edge computational and experimental chemistry and biology with laser-focused clinical development,' said Keith Flaherty, a board member and director of clinical research at Massachusetts General Hospital Cancer Center, in a statement. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Business Wire
11-06-2025
- Business
- Business Wire
Antares Therapeutics Launches with $177 Million to Develop First-in-Class Precision Medicines for Cancer and Other Serious Diseases
BOSTON--(BUSINESS WIRE)--Antares Therapeutics, Inc. ('Antares'), a biotechnology company developing first-in-class precision medicines for cancer and other serious diseases, launched today with $177 million in Series A financing. The financing was co-led by Omega Funds, Atlas Venture, Lightspeed Venture Partners, BVF Partners, and Cormorant Asset Management, with participation from Vinyanshu Ventures, Abingworth, Invus, Tenmile, Vida Ventures, and Willett Advisors. Antares is a spin-out of Scorpion Therapeutics, Inc. ('Scorpion'), which sold its mutant-selective PI3Kα inhibitor program, STX-478, to Eli Lilly and Company ('Lilly') in March 2025 for up to $2.5 billion in total consideration. Scorpion was founded in 2020 and, in the subsequent five years, raised a total of $420 million in financing, executed partnerships with multiple pharmaceutical companies, and generated six development candidates, three of which are in clinical testing. Antares is led by Scorpion's former executive leadership team and is advancing a pipeline of small molecule assets developed at Scorpion, including programs in precision oncology and other therapeutic areas, as well as programs initiated through Scorpion's 2022 transcription factor collaboration with AstraZeneca. 'We took our name from Antares, the brightest star in the Scorpius constellation, and known as 'the heart of the Scorpion.' We are building from a strong foundation with a team of experts who are experienced in making new medicines, as well as proprietary drug discovery capabilities and a robust preclinical pipeline fueled by discoveries in drugging previously inaccessible targets,' said Adam Friedman, M.D., Ph.D., Chief Executive Officer of Antares and former Chief Executive Officer of Scorpion. 'We are committed to leveraging our expertise to address well-validated, first-in-class targets across oncology and other serious diseases, and to continuing to execute a fast-to-clinic strategy to bring medicines to patients in need.' 'At Omega, we focus on identifying approaches and working with exceptional teams to deliver impactful products to patients,' said Otello Stampacchia, Ph.D., Founder and Managing Director at Omega Funds. 'Antares meets each of these criteria. As one of the founding investors in Scorpion, we have had the opportunity to follow the company's evolution very closely and have been consistently impressed by the breadth of the team's capabilities, as well as their scientific rigor and rapid execution. I look forward to seeing the company's vision advance by delivering differentiated, first-in-class products to treat some of the most important unmet medical needs.' Additionally, Antares announced that Pierre Fabre Laboratories, with whom Scorpion previously partnered to advance two clinical-stage, highly selective next-generation mutant EGFR inhibitors for the treatment of non-small cell lung cancer, has acquired global rights to both programs. Under the terms of the agreement, Pierre Fabre Laboratories will lead the continued clinical development and global commercialization of both programs, and Antares will be eligible to receive regulatory and commercial milestones and tiered royalties. Antares' leadership team Antares is led by the former Scorpion executive team, including leaders with accomplished track records in the biotechnology industry: Adam Friedman, M.D., Ph.D., Chief Executive Officer Natasja Brooijmans, Ph.D., Executive Vice President, Discovery Predictive Sciences Mark Chao, M.D., Ph.D., Chief Medical Officer Andrew Fedder, General Counsel Angel Guzman-Perez, Ph.D., Executive Vice President, Head of Chemistry Erica Jackson, Ph.D., Chief Scientific Officer Darrin Stuart, Ph.D., Chief Development Officer Amanda Valentino, Chief People Officer The company's Board of Directors are industry veterans with company-building expertise, as well as experience pioneering breakthrough medicines: Jeff Albers, J.D., M.B.A., Board Chair at Antares Therapeutics and Venture Partner at Atlas Venture Shelley Chu, M.D., Ph.D., Partner at Lightspeed Venture Partners Keith Flaherty, M.D., Director of Clinical Research at Massachusetts General Hospital Cancer Center and Professor at Harvard Medical School Jean-François Formela, M.D., Partner at Atlas Venture Adam Friedman, M.D., Ph.D., Chief Executive Officer of Antares Therapeutics Sir Menelas Pangalos, Ph.D., formerly Executive Vice President of Biopharmaceuticals R&D at AstraZeneca 'After years of investment into its proprietary drug discovery capabilities, the team at Antares has made notable progress to unlock the therapeutic potential of targets long seen as important – but undruggable – like the large class of transcription factors,' said Sir Menelas Pangalos, Ph.D., independent member of the Antares Board. 'I look forward to partnering with the Antares team as they address some of the most complex challenges in science.' 'Antares will build on what Scorpion started: combining cutting edge computational and experimental chemistry and biology with laser-focused clinical development,' said Keith Flaherty, M.D., Director of Clinical Research at Massachusetts General Hospital Cancer Center. "This team has demonstrated an ability to break through longstanding limits in medicinal chemistry to advance a pipeline of first-in-class assets, aiming to change the treatment landscape for patients.' About Antares Therapeutics Antares Therapeutics is a biotechnology company developing transformational, first-in-class precision medicines with a focus on validated, undruggable targets in cancer and other serious diseases with large unmet need. Antares' most advanced program is expected to enter the clinic in 2026, with multiple additional programs in preclinical development. To learn more, visit and follow us on LinkedIn.
